In this broadcast of EAU TV, EAU Adjunct Secretary-General and Executive Member Science, Prof. Arnulf Stenzl (DE), led discussions on vital topics on bladder cancer (BCa) and renal cell carcinoma (RCC).
Posted on
Previous Article
« Best of EAU: Immune cell populations have prognostic value in RCC Next Article
Letter from the Editor »
« Best of EAU: Immune cell populations have prognostic value in RCC Next Article
Letter from the Editor »
Table of Contents: EAU 2021
Featured articles
EAU TV: Robotic surgery and advanced prostate cancer
LUTS & BPH
Best of EAU: The surgical armamentarium is evolving
IPSS: Visual alternatives to aid comprehension and new risk prediction models
Urinary Tract Infections
Prophylactic treatments for recurrent urinary tract infections
Failure of conservative management in emphysematous pyelonephritis
Antibiotic treatment of healthcare-associated infections
Prostate Cancer
EAU TV: Robotic surgery and advanced prostate cancer
EAU TV: The best on prostate cancer and incontinence & andrology
Best of EAU: Updates on imaging and treatment of prostate cancer
Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC
177Lu-PSMA-617: A new class of effective therapy
Testis and Penile Cancer
Best of EAU: New advances in testicular and penile cancer
Recommendations for the management of indeterminate small testis masses
Residual tumour resection in case of elevated markers
Bladder Cancer
Best of EAU: Highlights on bladder cancer
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma
Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy
Renal Cancer
Best of EAU: Immune cell populations have prognostic value in RCC
KEYNOTE-564: First positive phase 3 results with adjuvant checkpoint inhibition in RCC
PSMA PET-CT more accurate than standard-of-care imaging in RCC
Worse renal function after radical versus partial nephrectomy
Related Articles
November 24, 2021
Belzutifan shows benefit in two conditions that spark tumor growth
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy